"Epigenetic Reason For Drug Resistance Discovered In A Deadly Melanoma"
Mount Sinai researchers have discovered a previously unknown reason for drug resistance in a common subtype of melanoma, one of the deadliest forms of cancer, and in turn, have found a new therapy that could prevent or reverse drug resistance for melanoma patients with a particular gene mutation, according to a study published in Nature Communications in August. "The incidence of cutaneous malignant melanoma is rising and its therapeutic management remains challenging," said lead researcher Emily Bernstein, PhD, associate professor of oncological sciences and dermatology at the Icahn School of Medicine at Mount Sinai.
- Emily Bernstein, PhD, Associate Professor, Oncological Sciences, Dermatology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage: